Jnanadeva Bhat - Head-Formulation R&D, ACG; Manali Dalvi - Lead- Whitepaper and Publications, (Pharma & Nutra), ACG.
As the growth trajectory of pharmaceutical dosage forms continues to evolve, the sector is driven by advances in science, and technology, increased patient needs, and changing market dynamics.
This article explores the compelling marketing trends attributed to the shifts and innovations that are propelling the pharmaceutical industry toward a promising future – underpinned by the need to support healthcare needs. Additionally, it will highlight the advantages and significance of this era of expanding patient-centric dosage forms and fixed-dose combinations.
Innovations Propelling the Pharmaceutical Frontier
Now, perhaps more than ever before, it is an exciting time to delve into the trends that are shaping the future of drug delivery. Innovation is accelerating the pace of the therapeutic process and helping to achieve the pharmaceutical sector’s transformative shift from life science to healthcare.
The current landscape is undergoing profound changes - from personalized medicine and advanced nanotechnology to sustainable formulations, 3D printing, complex generics, as well as combination and smart drug delivery. The advances in fields such as genetics, molecular biology, and biotechnology have paved the way for the development of complex therapies. In addition, the increasing focus on rare diseases has showcased the pharmaceutical industry’s responsiveness to unmet medical requirements. For instance, the development and approval of gene therapies for rare genetic disorders, such as spinal muscular atrophy (SMA) or certain types of inherited blindness, highlight the industry’s commitment to addressing the needs of patients with rare diseases. These breakthrough treatments signify a paradigm shift, underscoring the pharmaceutical sector’s dedication to finding innovative solutions for previously overlooked medical conditions.
Historically, the landscape of new drug development has been marked by lengthy timelines and substantial costs, often taking several years from inception to completion of clinical processes. These challenges have hindered innovation and accessibility to life-changing therapies. However, a transformative shift to the use of cutting-edge trends such as AI (artificial intelligence), statistical data analysis, continuous manufacturing processes, blockchain technology, and real-world data utilization is driving a paradigm shift. These technological advances are not only supporting medication delivery but also delivering the entire spectrum of development, packaging, and final product distribution to end consumers. This dynamic convergence has reshaped the way drugs are perceived, as well as significantly reducing both the time and expense associated with their development. Strategic implementation in production workflows has also reduced the burden on human resources and significantly boosted production yields, effectively minimizing undesirable variations.
These new technologies and the benefits they bring are now fueling innovation in healthcare.
Revolutionizing Pharmaceuticals: The Era of Fixed-Dose Combinations
As highlighted above, the evolution of drug dosage forms is influenced by a multitude of trends. It is challenging to pinpoint a single trend as being more influential, as their impact often depends on the specific therapeutic context and the goals of drug delivery. However, some trends have acquired more attention and have the potential to reshape the pharmaceutical industry in substantial ways. Notably, the growing interest in oral medication has highlighted the significance of fixed-dose combination (FDC) therapies. This offers a streamlined program, meeting patients’ needs and improving the therapeutic outcome, reflecting the industry’s commitment to advancing patient-centric care and optimizing drug delivery methods for improved patient outcomes. Moreover, these therapies actively prioritize patient well-being by identifying unmet medical needs and addressing gaps in existing treatments.
As the pharmaceutical landscape evolves, the development and incorporation of Fixed-Dose Combinations (FDCs) continue to be a pivotal strategy for ensuring the longevity and competitiveness of pharmaceutical products in the market. These are typically presented as coformulations, wherein two or more active ingredients are incorporated into a single dosage form. This combination can consist of either pre-existing compounds or a blend of marketed and novel compounds. Taking a strategic approach offers manufacturers the opportunity to extend the lifecycle of a product, especially as it approaches the loss of exclusivity.
The rationale behind utilizing FDCs lies in creating a formulation that safeguards the product from generic and biosimilar competitors. By combining active ingredients within a single dosage form, manufacturers can potentially enhance the therapeutic efficacy, improve patient adherence, and offer a distinct advantage in the market – enabling a more streamlined and convenient treatment option for the consumer.
The market report for Fixed Dose Combination (FDC) Drugs predicts a robust Compound Annual Growth Rate (CAGR) of 6.75% spanning from 2023 to 2031, indicating significant global expansion.1 The worldwide FDC market is systematically divided into well-defined segments, covering North America, Latin America, Europe, South Asia, East Asia, Oceania, the Middle East, and Africa. North America emerges as the frontrunner, poised to assert dominance in the FDC market owing to remarkable advancements within the healthcare sector. Following closely are Europe and the Asia Pacific region, both contributing significantly to the global FDC market, due to their combined large populations, coupled with the increase in healthcare awareness.2
Strategic Advantages of FDCs
FDCs are prescribed more regularly, due to their increased efficacy and reduced side effects compared to newer techniques. This therapy is particularly beneficial in the treatment of infectious diseases, where a single drug can lead to the development of resistance. FDCs make it more challenging for pathogens to develop resistance to multiple drugs simultaneously as they contain two or more active ingredients that target different aspects of a disease or condition. This can also result in a synergistic effect, increasing the efficacy of the therapy. Furthermore, combining multiple drugs into a single formulation simplifies the treatment regimen for patients. This leads to improved adherence to prescribed therapies, as patients are more likely to follow their medication schedules when the number of pills or doses is reduced.
FDCs are carefully formulated to ensure that the individual drugs are compatible, and the dosages are appropriate for the intended therapy. This formulation strategy helps to avoid issues such as overdosing, which can occur when separate drugs are prescribed. It can also be more cost-effective, as it reduces the need for multiple prescriptions and co-payments. Additionally, they can lower healthcare system costs by streamlining treatment and improving patient adherence.
For manufacturers, the formulation of FDCs has opened up opportunities to develop potential proprietary products that offer substantial cost savings compared to both new chemical entities and their generic counterparts. This strategy not only furnishes them with fortified intellectual property support to prolong market exclusivity but also streamlines the development and regulatory approval process for a single FDC, making it more efficient and cost-effective than dealing with multiple individual drugs. Furthermore, this approach empowers formulators to push the boundaries of pharmaceutical innovation, presenting a wider array of treatment options. Formulators have a diverse toolkit for FDC development, including combination-filled dosage forms, multi-particulate systems, bi-layer, and multi-layer systems, active film coating, hot-melt co-extrusion, hot fusion, spray drying, as well as the incorporation of cutting-edge 3D printing technology. By strategically deploying these techniques, formulators optimize the advantages and effectively overcome the challenges associated with FDC development, thereby contributing to the progress of pharmaceutical science and patient care.
FDC’s in Capsule Dosage Form
Today, a wide array of capsule-based fixed-dose combinations is readily available to address diverse medical conditions, spanning from pain and inflammation to hypertension, diabetes, malaria, tuberculosis, and HIV/AIDS. The capsules serve as a versatile platform that aligns seamlessly with this emerging trend in medication customization.
Inert in nature, capsule shells do not react with the combination fill inside. They are available in various sizes tailored for pharmaceutical applications – ranging from #00 to #5, – and can be customized to meet specific manufacturing requirements.
FDC capsules encapsulate two or more active pharmaceutical ingredients (APIs) in a single shell. The combination of drugs possesses complementary therapeutic effects, enabling them to target different aspects of a medical condition. It also offers a means for delivering chemically incompatible actives by physically separating these actives, and by doing so preventing interactions that could reduce effectiveness or potentially cause adverse reactions.
Additionally, advancements in filling technology have made multiple encapsulation processes accessible, allowing for the incorporation of a diverse range of fixed-dose combinations, regardless of the dosage form. It has unlocked the door to encapsulate a wide range of potential constituents within capsules, including powders, pellets, and semi-solids, as well as various liquid forms including solutions, suspensions, and emulsions.
Depending on the formulation, capsules can be designed for immediate release, sustained release, or other controlled-release profiles. This capability provides better control over the timing and rate of drug release, optimizing the therapeutic efficacy of FDCs.
Furthermore, FDCs stand out as a strong option for inhalation drug delivery systems. Leveraging the partial filling technique, a minimal quantity of the active substance can be efficiently placed within the capsule. This approach enhances safety and convenience in inhalation therapy as patients only need to administer a single capsule. This simplicity can be particularly beneficial for individuals who may struggle with complex inhalation regimens, contributing to a more user-friendly and patient-centric inhalation experience.
Examples include: Glycopyrrolate+ Formoterol Fumarate+ Fluticasone Propionate- for treatment of COPD; Aspirin+ Dipyridamole, Atorvastatin + Aspirin- for management of stroke; Tamsulosin + Tadalafil, Tamsulosin + Dutasteride- for treatment of benign prostatic hyperplasia and erectile dysfunction; Aspirin + Ramipril + atorvastatin- for cardiovascular treatment; Pregabalin + Duloxetine- for the treatment of Neuropathic pain; Fluticasone + Vilanterol- for treatment of asthma; Dutasteride + Silodosin- for treatment of the symptoms of benign prostatic hyperplasia (BPH) in men; and Ibuprofen + Paracetamol- for acute pain.
Conclusion
In the ongoing move towards innovation and personalized care within the pharmaceutical sector, it has become imperative for manufacturers to stand at the forefront of this evolution. The industry is consistently researching ways to enhance existing medicinal products, aiming to broaden access to modern therapies and promote patient compliance. Fixed dose combinations are a valuable method to enhance the effectiveness of drug treatments, while simultaneously reducing side effects. The strategic development of these combinations becomes crucial for managing their product life cycles andexpandingg patents - providing a dual advantage for pharmaceutical companies. It also provides a simplified method for increasing consumer compliance.
Moreover, capsules have distinctly risen to prominence as the favored and versatile medium for delivering FDCs among the array of available dosage forms. Their adaptability and compatibility position capsules as pivotal facilitators, playing a crucial role in furnishing advanced, personalized, and effective healthcare solutions tailored to meet the evolving needs of patients on a global scale.
Reference
1. https://www.growthplusreports.com/inquiry/request-sample/ fixed-dose-combination-drugs-market/8498
2. https://www.persistencemarketresearch.com/market-research/ fixed-dose-combination-drugs-market.asp
Publication Detail
This article appeared in Tablets and Capsules Magazine Vol. 22, No. 1Jan/FebPages: 26-29